5.98
price up icon4.91%   0.28
pre-market  Vorhandelsmarkt:  5.98  
loading
Schlusskurs vom Vortag:
$5.70
Offen:
$5.69
24-Stunden-Volumen:
2.84M
Relative Volume:
1.64
Marktkapitalisierung:
$792.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-20.62
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
+5.28%
1M Leistung:
-5.30%
6M Leistung:
+37.16%
1J Leistung:
+123.13%
1-Tages-Spanne:
Value
$5.53
$6.075
1-Wochen-Bereich:
Value
$5.41
$6.075
52-Wochen-Spanne:
Value
$2.36
$7.48

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name
Firmenname
Trevi Therapeutics Inc
Name
Telefon
203-304-2499
Name
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Name
Mitarbeiter
31
Name
Twitter
@TreviThera
Name
Nächster Verdiensttermin
2025-03-18
Name
Neueste SEC-Einreichungen
Name
TRVI's Discussions on Twitter

Vergleichen Sie TRVI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TRVI
Trevi Therapeutics Inc
5.98 792.62M 0 -29.07M -31.85M -0.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-28 Eingeleitet H.C. Wainwright Buy
2025-03-10 Bestätigt Needham Buy
2025-03-10 Hochstufung Raymond James Outperform → Strong Buy
2024-12-12 Bestätigt H.C. Wainwright Buy
2024-09-09 Fortgesetzt Leerink Partners Outperform
2024-08-30 Eingeleitet H.C. Wainwright Buy
2024-08-30 Eingeleitet Raymond James Outperform
2024-06-13 Eingeleitet Rodman & Renshaw Buy
2023-04-12 Eingeleitet B. Riley Securities Buy
2022-11-22 Eingeleitet SVB Leerink Outperform
2019-06-03 Eingeleitet BMO Capital Markets Outperform
2019-06-03 Eingeleitet Needham Buy
2019-06-03 Eingeleitet SVB Leerink Outperform
2019-06-03 Eingeleitet Stifel Buy
Alle ansehen

Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten

pulisher
Jun 17, 2025

Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks

Jun 17, 2025
pulisher
Jun 14, 2025

Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Acquires Shares of 14,059 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - Eastern Progress

Jun 09, 2025
pulisher
Jun 09, 2025

WilmerHale Advises Trevi Therapeutics, Inc. in $115 Million Public Offering - WilmerHale

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Invests $66,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Closes Public Offering - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritte - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | TRVI Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Secures Massive $115M Funding: Investors Rush to Back Chronic Cough Treatment Developer - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Announces Pricing of $100 Million Underwritte - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by BNP Paribas Financial Markets - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Announces Public Offering Pricing - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics IncExpects Cash Resources To Fund Operations Into 2029 - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Eastern Progress

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Longview News-Journal

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Buys 9,589 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Biotech Trevi Therapeutics Secures Major $100M Financing Through Stock Offering - Stock Titan

Jun 04, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright maintains Trevi Therapeutics stock rating following trial results - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - Insider Monkey

Jun 03, 2025
pulisher
Jun 03, 2025

Stifel reiterates buy rating for Trevi Therapeutics stock after study results - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Oppenheimer Adjusts Price Target on Trevi Therapeutics to $23 From $20, Maintains Outperform Rating - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics stock soars to 52-week high of $7.43 By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics launches $100 million stock offering By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at D. Boral Capital - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics stock soars to 52-week high of $7.43 - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Terminates ATM Prospectus with Leerink - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer raises Trevi Therapeutics stock price target to $23 By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics launches $100 million stock offering - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Plans $100 Million Stock Sale; Shares Sliding in After-Hours Trade - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer Boosts Trevi Therapeutics (TRVI) Price Target to $23 | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Capital | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics (TRVI) Launches $100M Public Offering | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Announces Proposed Public Offering of Common Stock | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

trevi therapeutics reports positive results from phase 2b cough trial By Investing.com - Investing.com Australia

Jun 02, 2025

Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Trevi Therapeutics Inc-Aktie (TRVI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
SCIASCIA THOMAS
Chief Scientific Officer
Mar 25 '25
Sale
6.60
2,631
17,365
221,373
GOOD JENNIFER L
President & CEO
Mar 21 '25
Option Exercise
1.43
5,263
7,526
218,576
GOOD JENNIFER L
President & CEO
Mar 21 '25
Sale
6.58
5,263
34,625
213,313
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):